ArticleGene therapy2003
A model for the analysis of nonviral gene therapy.
Article in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Mechanisms and Strategies for Enhancing DNA Nuclear Entry in Gene Delivery.Cellular and molecular bioengineering · 2026Article
- Copy number of naked DNA delivered into nucleus of mammalian cells by electrotransfection.Bioelectrochemistry (Amsterdam, Netherlands) · 2023Article
- A statistical framework for determination of minimal plasmid copy number required for transgene expression in mammalian cells.Bioelectrochemistry (Amsterdam, Netherlands) · 2021Article
- Quantification of cellular and nuclear uptake rates of polymeric gene delivery nanoparticles and DNA plasmids via flow cytometry.Acta biomaterialia · 2016Article
- Time-Delayed Models of Gene Regulatory Networks.Computational and mathematical methods in medicine · 2015Review
- Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization.Respiratory research · 2014Article
- Computational modeling reveals optimal strategy for kinase transport by microtubules to nerve terminals.PloS one · 2014Article
- Investigation of Polyethylenimine/DNA Polyplex Transfection to Cultured Cells Using Radiolabeling and Subcellular Fractionation Methods.Molecular pharmaceutics · 2013Article
- Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes.Nanomedicine : nanotechnology, biology, and medicine · 2013Article
- In vitro efficient transfection by CM₁₈-Tat₁₁ hybrid peptide: a new tool for gene-delivery applications.PloS one · 2013Article
- Subcellular trafficking and transfection efficacy of polyethylenimine-polyethylene glycol polyplex nanoparticles with a ligand to melanocortin receptor-1.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Quantitative comparison between poly(L-arginine) and poly(L-lysine) at each step of polyplex-based gene transfection using a microinjection technique.Science and technology of advanced materials · 2012Article
- Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.Pharmaceutical research · 2010Review
- The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Quantitative comparison of intracellular unpacking kinetics of polyplexes by a model constructed from quantum dot-FRET.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Intracellular kinetics of non-viral gene delivery using polyethylenimine carriers.Pharmaceutical research · 2007Article
- Delivery and mechanistic considerations for the production of knock-in mice by single-stranded oligonucleotide gene targeting.Gene therapy · 2007Article
- Understanding intracellular transport processes pertinent to synthetic gene delivery via stochastic simulations and sensitivity analyses.Biophysical journal · 2007Article
- Intracellular trafficking of plasmids for gene therapy: mechanisms of cytoplasmic movement and nuclear import.Current gene therapy · 2006Review
- Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging.Nucleic acids research · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Further understanding of the mechanisms involved in cellular and intracellular delivery of transgene is needed to produce clinical applications of gene therapy. The compartmental and computational model designed in this work is integrated with data from previous experiments to quantitatively estimate rate constants of plasmid translocation across cellular barriers in transgene delivery in vitro. The experimental conditions between two cellular studies were held constant, varying only the cell type, to investigate how the rates differed between cell lines. Two rate constants were estimated per barrier for active transport and passive diffusion. Translocation rates of intact plasmid across the cytoplasmic and nuclear barriers varied between cell lines. CV1 cells were defined by slower rates (0.23 h(-1) cytoplasmic, 0.08 h(-1) nuclear) than those of the HeLa cells (1.87 h(-1) cytoplasmic, 0.45 h(-1) nuclear). The nuclear envelope was identified as a rate-limiting barrier by comparing the rate of intact plasmid translocation at each barrier. Slower intact plasmid translocation in CV1 cells was correlated with a reduced absolute capacity for transgene efficiency in comparison with HeLa cells. HeLa cells were three times more efficient than CV1 cells at producing green fluorescent protein per intact plasmid delivered to the nucleus. Mathematical modeling coordinated with experimental studies can provide detailed, quantitative understanding of nonviral gene therapy.
Indexed as
Identifiers
12939643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.